Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

RSS icon
The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

FDA panel votes not to endorse Medtronic renal denervation system

The vote was close, initially ending with a tie, but the panel ultimately decided there were too many questions related to the device's long-term benefits for patients with uncontrolled hypertension.

Recor Medical's Paradise Ultrasound Renal Denervation System

FDA panel votes in favor of Recor Medical renal denervation system

A few members of the panel did question the device's efficacy and long-term durability. The FDA will now use these findings to make its final decision related to the system's approval. 

doctor with overweight patient who may be treated with TAVR or surgery

Weight loss drug semaglutide could boost heart health of up to 93M patients in US alone

Researchers have recently determined that the medication, originally developed to treat diabetes, can contribute to weight loss and reduce a patient's MACE risk by up to 20%. 

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients

Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

Hari Naidu, MD, explains that inconsistent diagnostic imaging and how it is reported has likely led to a major underdiagnosis of HCM. #ASE #ASE2023 #HCM

Why hypertrophic cardiomyopathy may be widely underdiagnosed

One expert believes the lack of standardization for how diagnostic imaging in conducted and reported has led to a major underdiagnosis of HCM.

Lisa Salberg, CEO of the Hypertrophic Cardiomyopathy Association (HCMA) explains how the group has helped improve HCM patient care.

Hypertrophic Cardiomyopathy Association has helped advance HCM care

The Hypertrophic Cardiomyopathy Association (HCMA) has helped guide and advance HCM care not only for patients, but also for hospitals and physicians. 

Peter Libby, MD, explains how infections cause heart attacks. This came out of research taking a close look at COVID, but the inflammation from any infection may cause increased inflammation of coronary plaques that cause heart attacks. #COVID #COVID19

Do infections cause heart attacks? Lessons from COVID

COVID-19 opened the eyes of many cardiology researchers that infections may promote inflammation in atherosclerotic plaques, leading to cardiac events.

Matt Martinez, MD, Morristown Medical Center HCM program, explains how hypertrophic cardiomyopathy patient management is changing.

Exercise plays a key part in HCM management

Matthew Martinez, MD, detailed the many ways HCM care management is changing during an exclusive interview at ASE 2023.

Displaying 193 - 200 of 999
Design by Adaptive Theme